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ABSTRACT

EFFECTS OF PRENATAL EXPOSURE TO PHENOBARBITAL ON VERBAL
ABILITIES IN SCHOOL-AGED CHILDREN

August 2020

Jocelyn M. Lutes, B.S., Viterbo University
B.A., Viterbo University
M.S., University of Massachusetts Boston

Directed by Professor Jane Adams

Phenobarbital is one of the oldest medications used for the treatment of epilepsy.
Although its use has declined in many developed nations, phenobarbital is still a first-line
treatment in several developing countries across the globe. If possible, current American
Academy of Neurology guidelines advise against the use of phenobarbital during pregnancy
due to an increased risk for structural malformations. However, less is known about the risk
that prenatal exposure to phenobarbital poses to the cognitive and behavioral development of
the child. Adams et al (in progress) have shown that, in comparison to demographically
iv

matched controls, children prenatally exposed to phenobarbital for the treatment of maternal
epilepsy have a significant reduction in general mental ability and verbal intelligence. In this
paper, we aim to further explore the impact of prenatal exposure to phenobarbital on verbal
abilities by examining performance on individual verbal subtests within the original testing
battery. The performance of children that were prenatally-exposed to phenobarbital and
demographically matched controls was compared on a selection of verbal subtests from the
Wechsler Intelligence Scale for Children, 3rd Edition (WISC-III ), the Stanford-Binet
Intelligence Scales, 4th Edition (SB-IV), and the Wechsler Memory Scale, Revised (WMSR). Maternal intelligence was assessed with the Wechsler Abbreviated Intelligence Scale,
Revised (WAIS-R). Initial analyses were conducted to explore the effects of sex and
treatment on verbal performance. However, no significant effects of sex nor any interaction
effects were found, so sex was removed from later analyses. ANCOVA controlling for
maternal intelligence confirmed a significant reduction in general mental ability and verbal
intelligence in the sample of children prenatally exposed to phenobarbital. Multivariate
ANCOVA controlling for maternal intelligence revealed a significant effect of exposure
group on verbal performance across measures. Follow-up analyses revealed that children
prenatally exposed to phenobarbital performed significantly worse than controls on the
Vocabulary and Arithmetic subtests from the WISC-III and on a test of Story Memory from
the WMS-R. Combined with previous findings by Adams et al., the results of this study
further support an effect of prenatal exposure to phenobarbital on children’s verbal abilities.
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CHAPTER 1
INTRODUCTION

According to the World Health Organization (WHO), there are approximately 50
million people living with epilepsy worldwide (World Health Organization, 2019). It is
estimated that 25% of individuals living with epilepsy are women of childbearing age
(Pennell et al., 2012) and in the United States alone, approximately three to five per 1000
births are to a woman with epilepsy (Harden et al., 2009). Historically, understanding the
risks that maternal epilepsy during pregnancy poses to the fetus has been challenging, as it
has been difficult to disentangle the risks associated with the disorder from the risks caused
by exposure to antiepileptic medications (Holmes et al., 2001). Some researchers originally
suggested that structural teratogenic effects seen in infants born to women with epilepsy were
likely due to inheritance of genetic differences associated with maternal epilepsy (Gaily,
Granstrom, Hiilesma, & Brady, 1988). However, a growing body of literature began to amass
that compared the outcome of infants exposed to antiepileptic medications in utero with
infants of women with well-managed, untreated epilepsy and healthy controls. These studies
found that, while infants exposed to antiepileptic medications often exhibited physical
anomalies, infants of women with untreated epilepsy did not differ from controls (Nulman,
Scolnick, Chitaya, Farkas, & Koren, 1997; Holmes, Rosenberger, Harvey, Khosbin, & Ryan.,
2000; Holmes et al., 2001). In general, these studies, along with others, suggested a link
between antiepileptic medications and structural abnormalities and established the older
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antiepileptic medications, including carbamazepine, phenytoin, valproate, and phenobarbital,
as teratogens (Hill, Verniaud, Horning, McCulley, & Morgan, 1974; Hanson & Smith, 1976;
Seip, 1976; Jones, Lacro, Johnson, & Adams, 1989; Jones & Chambers, 1992; Nulman et al.,
1997; Holmes et al., 2000; Holmes et al., 2001). In addition, more severe teratogenic effects
were reported in infants exposed to treatment at higher doses and polytherapy treatment
regimens (Holmes et al., 2001; Harden et al., 2009).
For many women with epilepsy, discontinuation of medication during pregnancy is
not an option due to risks of maternal physical injury, mortality, or effects on infant birth
weight or prematurity (Battino & Tomson, 2007; Chen, Chiou, Lin, & Lin, 2009). Therefore,
management of treatment must aim to maintain or decrease seizure frequency while also
considering the risk that exposure to antiepileptic drugs poses to the fetus. Indeed, in order to
reduce the risk of congenital malformations and cognitive impairment, the American
Academy of Neurology (AAN) has recommended monotherapy at the lowest effective dose
and cautions against the use of polytherapy during pregnancy (Harden et al., 2009).
First discovered in 1912, phenobarbital is one of the oldest medications that has been
used to effectively treat epilepsy (López-Muñoz, Ucha-Udabe, & Alamo, 2005).
Phenobarbital exerts its primary anti-seizure effect through allosteric binding to the GABAA
receptor, leading to a prolonged influx of chloride and hyperpolarization of the postsynaptic
membrane (Rogawski & Porter, 1990). Treatment with phenobarbital has been associated
with adverse side effects in patients, including sedation, changes in mood, and impaired
cognition (Kwan & Brodie, 2004). When compared to healthy controls, patients with general
epilepsy who were treated with phenobarbital monotherapy showed adverse cognitive side
effects, including slowed motor movements, slower processing speed, and impaired attention
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(Manni et al., 1993). Furthermore, in a double-blind randomized trial in which patients with
partial and secondary generalized tonic-clonic seizures were assigned to a treatment group,
almost 50% of patients receiving phenobarbital withdrew from the study due to reported
toxicity (Mattson et al., 1985). Due to these adverse side effects and poor tolerability by
some patients, in the United States and many other developed nations, phenobarbital
prescriptions have decreased in favor of newer antiepileptic medications (Kwan & Brodie,
2004; Brodie & Kwan, 2012), including during pregnancy (Meador et al., 2018). However,
due to its low cost and high efficacy, phenobarbital remains a first-line treatment for epilepsy
in low- and middle-income countries (World Health Organization, 2019).
During pregnancy, phenobarbital readily crosses the placenta and enters the fetal
chamber (Melchior, Svensmark, & Trolle, 1967). Because phenobarbital has been associated
with an increased risk of cardiac and oral cleft malformations (Hernández-Díaz et al., 2012),
current guidelines for treatment during pregnancy advise against the use of phenobarbital if
possible (Harden et al., 2009). However, in many nations, phenobarbital remains one of the
only treatment options (Kwan & Brodie, 2004), and while it has been established to have
structural teratogenic effects, less is known about how prenatal exposure to phenobarbital
impacts the cognitive and behavioral development of the offspring.
Some of the earliest evidence to suggest a neuroteratogenic risk of phenobarbital has
come from rodent models of gestational and neonatal exposure to the drug. Early research
established that gestational exposure to phenobarbital from mid-to-late gestation resulted in
decreased brain weight in exposed pups and reductions in cerebellar Purkinje cells and
hippocampal pyramidal cells (Yanai, Rosselli-Austin, & Tabakoff, 1979). Gestational
exposure has also resulted in behavioral alterations at several timepoints in development
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(Christensen, Gonzalez, & Rayburn, 2004). As pups, exposed mice demonstrated fewer
vocalizations following maternal separation and a greater startle response to a stimulus. As
adults, phenobarbital-exposed offspring showed decreased motor activity, increased startle to
a stimulus, increased anxiety-like behavior, and impaired learning on a tube runway.
Because the neonatal period from days 1 to 10 in rodents is estimated to align with the third
trimester in humans (Clancy, Finlay, & Darlington, 2007), models of neonatal exposure to
phenobarbital have also been used to inform the neuroteratogenic risk of the medication. Similar to
gestational exposure, treatment with phenobarbital from the first to third week resulted in reduced
brain weight in pre-weaning (Schain & Watanabe, 1975) and adolescent mice (Yanai & Bergman,
1981). The total area of the cerebellum and of the dentate gyrus of the hippocampus were also
reduced in mice treated with phenobarbital, and there was a reduction in cerebellar Purkinje and
granular cells and hippocampal pyramidal and granule cells (Yanai & Bergman, 1981). Within the
cerebellum, there were lasting decreases in dendritic spine densities of Purkinje cells (Yanai & Iser,
1981).

Noting the reduction in total brain weight and in specific populations of neurons in
phenobarbital-exposed animals, several groups have attempted to uncover possible
mechanisms of action, including impaired neurogenesis and increased apoptosis. Following
in utero phenobarbital exposure from mid- to late-gestation, there was decreased proliferation
of Purkinje cells, pyramidal cells, and cells of the cortex in young offspring (Yanai, Woolf,
Feigenbaum, 1982). Decreased proliferation was also seen throughout the brain following
neonatal treatment with phenobarbital during the first week of life and resulted in decreased
production of neurons at P15 (Stefovska et al., 2008). By adulthood, phenobarbital treated
mice showed impaired spatial memory and structural abnormalities in the hippocampus and
cingulate cortex (Stefovska et al., 2008). Combined, the results of these studies suggest that
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phenobarbital exposure during gestation and neonatal periods impairs cell proliferation and
neurogenesis and that these early alterations result in structural and functional brain
abnormalities that persist into later life.
In addition to impairing the birth of new cells, research has also suggested that
neonatal treatment with phenobarbital induces widespread apoptosis throughout the
developing brain. Treatment with phenobarbital throughout the first month of life resulted in
increased apoptosis throughout the brain, including in the hippocampus, thalamic nuclei,
subiculum, amygdala, hypothalamus, caudate nucleus, nucleus accumbens, and globus
pallidus (Bittigau, Sifringer, & Ikonomidou, 2003). Acute treatment with phenobarbital in
pups also induced apoptosis in the striatum, ventral thalamus, and lateral thalamus, and these
results were amplified by polytherapy treatment combined with lamotrigine (Katz, Kim,
Gale, & Kondratyev, 2007).
Combined, studies conducted in rodent models suggest that phenobarbital exposure
during periods of early brain development disrupts key developmental processes, including
neurogenesis and apoptosis, and results in widespread structural changes in the brain. In
addition to the previously described behaviors, rodents exposed to phenobarbital during the
gestational or neonatal periods have also shown behavioral alterations in adulthood,
including deficits in spatial learning and memory (Yanai, 1989; Forcelli et al., 2012;
Stefovska et al., 2008), impaired learning in a passive avoidance paradigm (Frankel et al.,
2016; Gutherz et al., 2014), decreased motor activity and coordination (Christensen et al.,
2004; Forcelli et al, 2012), impaired cued fear conditioning (Forcelli et al., 2012), increased
or decreased anxiety-like behavior (Christensen et al., 2004, Forcelli et al., 2012, Frankel et
al, 2016), and impaired prepulse inhibition (Forcelli et al., 2012; Gutherz et al, 2014). Given
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the structural changes that are seen in early development, several researchers have
hypothesized the link between early brain development and the behavioral changes seen at
later ages. Several behaviors, including spatial learning and memory and passive avoidance
have been attributed to early changes in hippocampal structure (Stevofska et al., 2008;
Frankel et al., 2016). Furthermore, Gutherz et al. (2014) hypothesized that deficits in passive
avoidance could also be linked to early apoptosis in the frontal cortex, leading to
impairments in executive functioning. Forcelli et al. (2012) considered early apoptosis in the
amygdala, striatum, and nucleus accumbens as a possible explanatory factor for impaired
prepulse inhibition in phenobarbital-exposed animals.
Overall, as illustrated above, although it is unclear how specific effects seen in
rodents are related to clinical outcomes in humans exposed to phenobarbital in utero, studies
in rodents raise concern about the possible lifelong neuroteratogenic effects of phenobarbital
exposure in early development. Despite this fact, however, less is known about cognitive and
behavioral outcomes in infants and children prenatally exposed to phenobarbital.
To date, several cohorts in North America and Europe have been established to study
how prenatal exposure to monotherapy with antiepileptic medications impacts the
neuropsychological functioning of the child at various ages in development, and these
cohorts have been pivotal in classifying the neuroteratogenic risk of antiepileptic
medications, such as phenytoin, carbamazepine, and valproic acid (Bromley & Baker, 2017).
Unfortunately, however, due to its frequent use in polytherapy regimens and to its declining
use in developed nations, phenobarbital has not been included as a primary medication of
interest in these studies (Lutes, Borchelt, Janulewicz, & Adams, 2018). Of the limited studies
that do exist for phenobarbital, the majority suggest that prenatal exposure to phenobarbital is
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not associated with adverse effects on neuropsychological functioning in toddlers (Thomas et
al., 2008) or children (Dean et al, 2002; Thomas, Sukumaran, Lukose, Geourge, & Sarma,
2007). One study, however, found poor performance in spelling and arithmetic for children
prenatally exposed to phenobarbital (van der Pol, Hadders-Algra, Huisjes, & Touwen, 1991),
and lowered verbal performance has been reported in adult men exposed to phenobarbital
during the prenatal period (Reinisch, Sanders, Mortensen, & Rubin, 1995). The
methodological rigor of these studies is questioned, however, by sample sizes less than 20
per exposure group (van der Pol et al., 1991; Dean et al., 2002; Thomas et al., 2007; Thomas
et al., 2008), lack of a comparison to a control group (Thomas et al., 2008), and failure to
adjust for possible confounding variables, such as maternal education and measures of
maternal mental ability (IQ scores) (van der Pol et al., 1991, Reinisch et al., 1995; Dean et
al., 2002; Thomas et al., 2007; Thomas et al., 2008).
Understanding the need for more research in this area, Adams et al. (manuscript in
progress) assessed the cognitive performance of 34 phenobarbital-exposed children and 34
unexposed control children that were matched for maternal age at delivery, maternal
socioeconomic status (including education), gender, and age at testing. Research on
phenytoin-exposed and carbamazepine-exposed children and their unexposed matches was
conducted in parallel and is not reported herein. Following adjustment for matching, siblings,
and maternal IQ, in comparison to their matched controls, children in the phenobarbitalexposed group exhibited a significant reduction in verbal IQ (VIQ) and full-scale IQ (FSIQ).
Because performance IQ (PIQ) did not differ significantly due to phenobarbital exposure,
reductions in full-scale IQ were interpreted as largely resulting from impaired performance in
verbal areas.
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In order to further explore the profile of cognitive strengths and weaknesses in
children prenatally exposed to phenobarbital, the current paper examines performance on
individual verbal subtests in the neuropsychological battery for a subset of subjects from
Adams et al. (in progress).
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CHAPTER 2
METHODS

Recruitment of Subjects
Recruitment of subjects was conducted in two phases. During Phase I (1983-1993),
the primary source of recruitment, women were recruited from a surveillance study being
conducted at five maternity hospitals in the Boston area (Holmes, Harvey, Brown, Hayes, &
Khoshbin, 1994; Holmes et al., 2001). During Phase II (1996-2000), additional subjects were
recruited through referrals from neurologists, pediatricians, and obstetricians/gynecologists
as well as through medical record evaluations by a large health maintenance organization in
the Boston area. Flyers, newspaper and radio advertisements, and referrals from other
subjects in the study were also used to recruit subjects from the community.
Selection of Subjects
Selection for participation in the study was dependent upon inclusion criteria,
exclusion criteria, and the ability to match between groups. Women were excluded from
participation in the study if they experienced one or more tonic-clonic seizures during
pregnancy, had exposure to polytherapy during pregnancy, or if they were exposed to a
known teratogen. Seizure and treatment histories were determined through medical record
review by a neurologist and exposure to a teratogen was assessed by a teratologist at
Massachusetts General Hospital. For inclusion in the study, both parents of the child had to
demonstrate normal intelligence on the Raven’s Progressive Matrices Test. If qualified for
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participation in the study, maternal intelligence was also assessed using the Weschler
Abbreviated Intelligence Scale (WAIS).
Participants were excluded from the study if the child was not a singleton birth, if the
child had a postnatal history of illness or injury that could impact neuropsychological
functioning, if the child had a visual or auditory impairment, or if English was not the child’s
first language. Evaluation of the presence of any of these criteria in children was assessed
through a review of medical records, a parental questionnaire, and auditory and visual
screening tasks.
If a subject met participation criteria, matching was then conducted in order to
balance the maternal and child demographics of exposed and unexposed participants.
Children from the phenobarbital exposure group were matched with an unexposed control
child. Matching criteria included maternal age at child’s birth, maternal socioeconomic status
(including education), child age at testing, and child sex.
Neuropsychological Assessments
Children in the original study were administered a comprehensive neuropsychological
screening battery that included the Wechsler Intelligence Scale for Children, Third Edition
(WISC-III) and select subtests from the Stanford-Binet Intelligence Scale, Fourth Edition
(SB-IV) and the Wechsler Memory Scale-Revised (WMS-R). All assessments were
conducted by a trained psychometrist that was blind to exposure group.
The WISC-III is a standardized assessment that provides composite scores of verbal
intelligence (VIQ), performance intelligence (PIQ) and full-scale intelligence (FSIQ). Verbal
subtests that were administered include Information (a test of general factual knowledge),
Arithmetic (a test of mental computation given verbal instructions), Vocabulary (a test of
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word knowledge), and Digit Span (a test of verbal short-term memory). Composite scores
have a mean of 100 and standard deviation of 15. Subtests have a mean score of 10 and a
standard deviation of 3. Both the VIQ and FSIQ were scored according to prorating criteria
described in the WISC-III manual (Wechsler, 1991).
The SB-IV is a standardized intelligence assessment comprised of 15 subtests that
provide an assessment of cognitive ability in verbal and non-verbal areas. In this study,
children were administered the Sentence Memory subtest as a measure of verbal memory.
This subtest has a mean scaled score of 50 and a standard deviation of 8 (Thorndike, Hagen,
& Sattler, 1986).
The WMS-R is a standardized memory assessment comprised of thirteen subtests
from which five index scores can be derived (Wechsler, 1987). To assess verbal memory
abilities, children were administered a task of immediate-recall story memory.
In addition to the assessment of children’s mental abilities, maternal intelligence was
assessed using the Wechsler Abbreviated Intelligence Scale-Revised (WAIS-R). The WAISR provides an assessment of VIQ, PIQ, and FSIQ. Composite scores have a mean of 100 and
standard deviation of 15 (Wechsler, 1981).
Statistical Analyses
To account for possible variance attributed by sibling relationships within the sample,
every effort was made to utilize one child per family and for the first-born child to be the one
included in analyses. There were two exceptions made, however, in order to provide
demographic, age, and gender matching and to protect sample size. In the unexposed control
group, there were two sets of siblings (4 subjects) that were matched to phenobarbital-
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exposed subjects. To balance the possible impact of sibling-based variance in the exposed
group, two sets of phenobarbital-exposed siblings were also retained.
The effectiveness of our matching was assessed by using two-tailed independent
samples t-tests to examine demographic characteristics of the exposed and unexposed groups.
Because this paper addresses a subset of phenobarbital-exposed children that were included
in the work by Adams et al., we were interested in confirming that our sample showed a
similar pattern of performance on the WISC-III as seen in the full sample (Adams et al., in
progress). Therefore, performance on the FSIQ, VIQ, and PIQ were examined using
univariate analysis of covariance in which exposure group and sex were included as factors
and maternal FSIQ was included as a covariate.
The effects of prenatal exposure to phenobarbital on verbal abilities were assessed
using multivariate analysis of covariance (ANCOVA), in which exposure group and sex were
included as factors and maternal FSIQ was included as a covariate. For this analysis, scores
on all verbal subtests in the battery were included as dependent variables. These subtests
included Information, Arithmetic, Vocabulary, and Digit Span from the WISC-III, Sentence
Memory from the SB-IV, and Immediate Recall Story Memory from the WMS-R. Upon
finding a significant multivariate effect, univariate ANCOVAs controlling for maternal FSIQ
were conducted to determine which specific dependent variables contributed to the
significant multivariate effect.
All analyses were conducted using IBM SPSS Statistics 27 for Macintosh, and all figures
were created using GraphPad Prism 8. Significance was assessed at p < 0.05.
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Approval for Work with Human Subjects
This study was approved by the Massachusetts General Hospital’s Human Studies
Committee and the University of Massachusetts Institutional Review Board. All parents
provided written informed consent, and if a child was fourteen years of age or older, they
were also asked to provide written assent prior to participating in their evaluation. No
families withdrew from the study once consent was obtained.
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CHAPTER 3
RESULTS

As shown in Table 1, the study population consisted of 26 phenobarbital (PB)exposed subjects and 26 unexposed controls. Demographic variables, such as age at testing,
maternal age at birth, and maternal education did not differ statistically between the two
groups (Age at Testing: t(50) = -0.030, p = 0.976), Maternal Age: t(48) = 0.676, p = 0.502),
Maternal Education: t(49) = 0.161, p = 0.873). Likewise, maternal FSIQ was similar between
the two groups (t(49) = -0.893, p = 0.376).
Unadjusted means and standard deviations for performance on the
neuropsychological measures are presented in Table 2. In general, for both exposure groups,
mean scores on all measures were consistent with performance in the average range or
higher. A determination of the number of children performing two standard deviations or
more below the mean revealed one subject from the PB-exposed group and no subjects from
the control group.
In initial confirmatory analyses, univariate ANCOVAs controlling for maternal FSIQ
were conducted to examine the effects of phenobarbital exposure and sex on individual
composite scores of the WISC-III. There was a significant effect of Exposure Group on FSIQ
(F(1,46) = 4.467, p = 0.040, η2p = 0.089) and VIQ (F(1,46) = 5.889, p = 0.019, η2p = 0.113),
but no effect on PIQ (F(1,46) = 2.009, p = 0.163, η2p = 0.042). There were no significant
effects of Sex (FSIQ: F(1, 46) = 1.598, p = 0.213, η2p = 0.034; VIQ: F(1,46) = 0.502,
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p = 0.482, η2p = 0.011; PIQ: F(1,46) = 3.174, p = 0.081, η2p = 0.065) and no Exposure
Group by Sex interaction (FSIQ: F(1,46) = 0.072, p = 0.790, η2p = 0.002; VIQ: F(1,46) =
1.188, p = 0.281, η2p = 0.025 ; PIQ: F(1,46) = 0.615, p = 0.437, η2p = 0.013. Therefore,
further analyses were conducted with Sex removed from the model. As shown in Table 3 and
Figure 1, ANCOVA controlling for maternal FSIQ revealed a significant effect of
phenobarbital exposure on FSIQ (F(1,48) = 4.967, p = 0.031, η2p = 0.094) and VIQ (F(1,48)
= 7.255, p = 0.010, η2p = 0.131), while PIQ (F(1,48) = 1.688, p = 0.200, η2p = 0.034) did
not significantly differ between the two groups.
After confirming decreased verbal performance on the WISC-III in our sample of PBexposed subjects, our primary interests were in determining if there was a difference across
verbal measures in our neuropsychological battery, and if so, which specific areas of verbal
cognition differed between groups. In initial analyses, multivariate ANCOVA controlling for
maternal FSIQ was conducted to examine the effects of phenobarbital exposure and sex on
the aggregate group of verbal subtests. As shown in Table 4, the analysis revealed a
significant effect of Exposure Group (F(6,39) = 2.584, Wilks’ Λ = 0.716, p = 0.033, η2p =
0.284). There was no significant effect of Sex (F(6,39) = 0.847, Wilks’ Λ = 0.885, p = 0.542,
η2p = 0.115) and no Exposure Group by Sex Interaction (F(6,39) = 1.01, Wilks’ Λ = 0.865, p
= 0.433, η2p = 0.135), so analyses were conducted with Sex removed from the model. The
adjusted means by Sex and Exposure Group are shown in Appendix A.
Multivariate ANCOVA controlling for maternal FSIQ revealed a significant effect of
exposure group on verbal measures (F(6, 41) = 2.647, Wilks’ Λ = 0.721, p = 0.029, η2p =
0.279). As shown in Table 5 and Figure 2, follow-up univariate between-group analyses
revealed no individually-significant differences in the scores of the PB-exposed and control
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children on Information (F(1,46) = 2.522, p = 0.119, η2p = 0.052), Digit Span (F(1,46) =
1.233, p = 0.273, η2p = 0.026), or Sentence Memory (F(1,46) = 1.744, p = 0.193, η2p =
0.037). However, PB-exposed children performed significantly worse than controls on
Vocabulary (F(1,46) = 4.743, p = 0.035, η2p = 0.093), Arithmetic (F(1,46) = 11.502, p =
0.001, η2p = 0.200), and Immediate Recall Story Memory (F(1,46) = 4.397, p = 0.042, η2p =
0.087).
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CHAPTER 4
DISCUSSION AND CONCLUSION

In a previous study, Adams et al. (in progress) found that children of women with
epilepsy that were prenatally exposed to phenobarbital monotherapy demonstrated
significantly lower verbal intelligence and full-scale intelligence on the WISC-III than
unexposed children born to women without epilepsy and matched for demographic variables.
Here, we have examined the effects of phenobarbital on specific verbal abilities assessed by a
group of verbal subtests selected from the WISC-III, the SB-IV, and WMS-R. We have
shown that, when compared to demographically matched, unexposed children, phenobarbitalexposed children performed significantly worse on a group of verbal subtests. Univariate
examination of performance on specific measures revealed significant effects on performance
on a test of word knowledge (Vocabulary), a test of mental arithmetic (Arithmetic), and a test
of verbal memory (IR-Story Memory).
Although the research investigating the effects of prenatal exposure to phenobarbital
on neurodevelopment is limited, our findings are consistent with current reported research.
Reinisch et al. (1995) retrospectively ascertained 33 adult men who had been exposed to
phenobarbital monotherapy in utero for reasons other than epilepsy (e.g. hypertension,
preeclampsia, eclampsia, sedation). When evaluated on the Wechsler Abbreviated
Intelligence Scale (WAIS), phenobarbital-exposed men demonstrated significantly lower
than predicted verbal intelligence. Although other antiepileptic medications, such as
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phenytoin, carbamazepine, valproic acid, and lamotrigine, exert their antiepileptic effects
through different initial mechanisms than phenobarbital, several researchers have also
reported a weakness in verbal abilities during at least one developmental timepoint in
prenatally exposed children (Meador et al., 2011, 2012; Nadebaum et al., 2001; Baker et al.,
2015). These common findings among different antiepileptic medications merit further
investigation to better understand possible common mechanisms, final common pathways, or
vulnerabilities.
The primary finding in this study was that, in comparison to controls, children
prenatally exposed to phenobarbital showed a significant overall weakness on measures of
verbal performance, with specific weaknesses on a test of mental arithmetic, story recall, and
vocabulary. Van der Pol et al. (1991) conducted neurodevelopmental follow-up on 12
prospectively ascertained children that had been prenatally exposed to phenobarbital
monotherapy for maternal epilepsy. When compared to demographically matched control
children, the phenobarbital-exposed group had significantly more children that performed
poorly on standardized tests of spelling and arithmetic, though the specific measures were not
described. Phenobarbital-exposed children in our study also demonstrated lower performance
on a test of vocabulary knowledge and had an impaired ability to immediately recall stories
that they had heard. To our knowledge, this is the first report of impaired performance on
these subtests in phenobarbital-exposed children.
It is unclear why children performed worse on Vocabulary, Arithmetic, and Story
Memory, while other verbal subtests, such as Information, Digit Span, and Sentence Memory
were not significantly impacted. Nicholson and Alcorn (1993) have discussed cognitive
abilities that influence high or low performance on subtests of the WISC-III. According to
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their assessment, performance on the Arithmetic subtest of the WISC-III relies on verbal
output ability, focused attention, ability to perform simple math, short-term memory, low
distractibility, and a good educational background. In their assessment, performance on the
Vocabulary subtest is also dependent on verbal output abilities and a good educational
background, but also requires an understanding of culture. Ernst, Warner, Morgan, Townes,
Eiler, and Coppel (1986) conducted a factor analysis of the Weschler Memory Scale and
found that focused attention and concentration abilities appear to be important factors in
determining performance on the story memory component of the assessment. Because
phenobarbital exposed subjects in this study performed similarly to controls on three
subtests, it is unlikely that generalized verbal output abilities are the primary contributor to
the differences in performance between groups. Due to the importance of attention and low
distractibility for performance on the Arithmetic and Story Memory subtests, however, it is
possible that the verbal working memory and attentional abilities required for these subtests
challenged the abilities of children prenatally exposed to phenobarbital. To further
understand the specific profile of cognitive strengths and weaknesses in phenobarbitalexposed children, future studies should include a neuropsychological battery that also
contains robust measures of working memory abilities, attention, and distractibility.
Although verbal abilities in humans are unable to be directly studied in rodent
models, the neuroteratogenic risk of phenobarbital can also be informed by animal models of
gestational and neonatal exposure to the drug. Few studies have examined behavioral
outcomes in pups or adolescent rodents, but behavioral alternations have been observed in
adult rodents exposed to phenobarbital during periods of early brain development. Of interest
to our study, Gutherz et al. (2014) reported that adult rats who were treated with
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phenobarbital in the neonatal period exhibited poor performance on a task of passive
avoidance. Although passive avoidance has been reported to be a hippocampal-dependent
behavior (Frankel et al., 2016), Gutherz et al. (2014) also hypothesized that deficits in
passive avoidance could be linked to early apoptosis in the frontal cortex, leading to deficits
in executive functioning in phenobarbital-exposed animals. Significant apoptosis in the
frontal cortex of P7 pups has been reported following acute exposure to phenobarbital in the
neonatal period (Bittigau, Sifringer, & Iknonomidou, 2003). Additionally, Bittigau, Sifringer,
& Ikonomidou (2003) also reported significant apoptosis following phenobarbital exposure
in two brain regions reported to be part of the brain network for verbal working memory in a
pediatric population (Yang et al., 2015), including the frontal cortex and cingulate cortex.
Currently, a direct link between research in animals and behavioral outcome in humans has
not been established, but more focused studies in animals at different developmental time
points will be pivotal to informing the risk that early phenobarbital exposure poses to the
development of the brain and behavior.
Although the animal literature suggests a neuroteratogenic risk of phenobarbital,
currently, it is unclear exactly how research in animal models relates to neuropsychological
outcomes in children that are exposed to phenobarbital in utero. However, Meador & Loring
(2016) have suggested a correlation between outcomes of apoptotic models of exposure to
antiepileptic medications and cognitive outcome in children. In an animal model of neonatal
phenobarbital-induced apoptosis, widespread programmed cell death was seen at plasma
concentrations of 25-35 μg/mL, a level stated to be of therapeutic relevance in human infants
administered phenobarbital (Bittigau, Sifringer, & Ikonomidou, 2003). In a small sample of
newborns exposed to phenobarbital in utero, average peak plasma concentration was 16.1
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μg/mL, but levels as high as 21.6 μg/mL were reported in some infants (Zuppa et al., 2011).
Although the mean phenobarbital concentration in prenatally exposed infants is thought to be
less than the concentration seen in Bittigau, Sifringer, & Iknomidou (2003), it is unknown if
lower concentrations of phenobarbital may result in apoptosis in light of potentially increased
vulnerability of the developing brain at earlier stages. However, due to the possible
association between drug-related apoptosis in animals and cognitive outcome in humans,
Meador & Loring (2016) have suggested that the United States Food and Drug
Administration require preclinical testing with apoptotic models to inform the
neuroteratogenic risk of new antiepileptic medications prior to their use in humans.
The results of our study add to the limited amount of literature exploring the
cognition of children prenatally exposed to phenobarbital. Specifically, our results suggest
decreased performance on a test of vocabulary, decreased mental arithmetic abilities, and
impaired verbal memory for stories in comparison to control children. Our study was limited
by small sample size, lack of confidence in the consistency of classifications of types of
maternal epilepsy, and incomplete information on doses of phenobarbital used throughout
pregnancy. In order to truly understand the full risk posed by prenatal exposure to
phenobarbital, future studies should examine dose-response relationships and risk of
teratogenicity by length of exposure, when possible. Despite these limitations, however,
strengths of our study include careful matching of exposed and control subjects on important
demographic variables; exclusion of pregnant women who had seizures during pregnancy,
polytherapy with other anticonvulsant medications, or exposures to other known teratogens;
use of standardized neuropsychological assessments conducted by examiners that were
blinded to exposure group: and statistical adjustment for maternal intelligence.
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Although phenobarbital use has declined in developed, industrial nations, for many
parts of the developing world there is a choice between treatment with phenobarbital or no
treatment at all (Kwan & Brodie, 2004). Combined with the results of Adams et al. (in
progress), this research suggests an effect of prenatal exposure to phenobarbital on verbal
abilities, specifically vocabulary knowledge, mental arithmetic, and immediate recall verbal
memory, that is consistent with previously published literature. Combined with animal
literature that provides mechanistic insight into morphological and functional changes that
occur in response to early phenobarbital exposure, these studies suggest that use of
phenobarbital during pregnancy poses a neuroteratogenic risk to the developing infant.
Future studies should aim to further explore neurodevelopmental outcomes in larger samples
of children prenatally exposed to phenobarbital monotherapy. Specific areas of research
could include exploring dose-response relationships, exposure durations, and outcomes
related to cognitive abilities, such as memory and attention. Furthermore, research should be
conducted to explore alternative efficacious and low-cost treatments for use in pregnant
women with epilepsy in developing nations.

22

Table 1 Demographic Characteristics of Study Population by Exposure Groupa
Children

Control
(n = 26)

PB-Exposed
(n = 26)

Age at Testing, Years

9.8 (2.7)

9.7 (2.7)

Age Range, Years

6.0-15.8

6.6-16.3

Sex (M:F)

11:15

11:15

Age at Child’s Birth, Years

32.5 (4.9)

33.3 (4.2)

Education, Years

15.9 (2.4)

16.0 (2.8)

Full Scale IQb

114.3 (12.8)

110.8 (15.1)

Mothers

a
b

Values are presented as mean (standard deviation)
Mean for the control group is based on 25 subjects.

23

Table 2 Unadjusted Scoresa on Neuropsychological Measures
WISC-III

Control
(n = 26)

PB-Exposed
(n = 26)

Full Scale IQ

113.12 (11.17)

102.88 (16.62)

Verbal IQ

115.19 (9.80)

103.88 (16.68)

Performance IQ

108.88 (13.27)

101.62 (16.13)

Information

12.96 (3.07)

11.31 (3.70)

Vocabulary

13.12 (2.92)

11.08 (3.53)

Arithmetic

12.31 (2.92)

9.12 (3.16)

Digit Span

11.23 (2.34)

10.46 (2.79)

10.58 (3.45)

8.67 (3.41)

54.17 (6.78)

52.13 (8.29)

WMS-Rb
Immediate Recall Story Memory
SB-IVb
Sentence Memory*
a

Values are presented as mean (standard deviation)
Means are based on 24 subjects per group.

b
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Table 3 Adjusted Means for Composite Scores of the WISC-III Following Univariate
ANCOVA Examining the Effect of Exposure Group While Controlling for Maternal FSIQ
Composite Score
Full Scale IQ
Verbal IQ
Performance IQ

Control
Adj. Mean
(95% CI)
111.88
(106.53 - 117.24)
114.46
(109.14 - 119.78)
107.28
(101.76 - 112.81)
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Control
Adj. Mean
(95% CI)
103.54
(98.29 - 108.79)
104.44
(99.23 - 109.66)
102.27
(96.85 - 107.68)

F value
(p-value)
4.967
(0.031)
7.255
(0.010)
1.688
(0.200)

125

125

*
Verbal IQ

Full Scale IQ

75
50

Performance IQ

100

100

75
50
25

25

0

0
Control

PB

125

*

100
75
50
25
0

Control

PB

Control

PB

Figure 1 Mean Composite Scores on the WISC-III by Exposure Group. Vertical bars
represent the 95% CI. Data were analyzed with univariate ANCOVA and adjusted for
maternal FSIQ, * p < 0.05.
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Table 4 Adjusted Means for Performance on Neuropsychological Measures Following
Multivariate ANCOVA to Examine the Effects of Exposure Group and Sex on Verbal
Abilities. Means are adjusted for maternal FSIQ.
Verbal Subtest
Information
Vocabulary
Arithmetic
Digit Span
Sentence Memory
Immediate Recall Story
Memory

Control
Adj. Mean
(95% CI)
12.59
(11.25 – 13.94)
12.88
(11.58 – 14.19)
12.07
(10.79 – 13.36)
11.13
(10.09 - 12.17)
54.45
(51.50 – 57.40)
10.92
(9.54 - 12.31)

PB-Exposed
Adj. Mean
(95% CI)
11.25
(9.89 – 12.61)
10.92
(9.59 – 12.24)
9.21
(7.90 – 10.52)
10.51
(9.45 - 11.56)
52.19
(49.19 – 55.18)
8.69
(7.28 - 10.10)
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F value
(p-value)
1.994
(0.165)
4.493
(0.40)
9.805
(0.003)
0.720
(0.401)
1.170
(0.285)
5.173
(0.028)

Table 5 Adjusted Means for Performance on Neuropsychological Measures Following
Multivariate ANCOVA to Examine Effects of Exposure Group on Verbal Abilities. Means
are adjusted for maternal FSIQ.
Verbal Subtest
Information
Vocabulary
Arithmetic
Digit Span
Sentence Memory
Immediate Recall Story
Memory

Control
Adj. Mean
(95% CI)
12.72
(11.42 - 14.02)
12.96
(11.70 - 14.23)
12.14
(10.90 - 13.39)
11.29
(10.27 - 12.32)
55.11
(52.12 - 58.11)
10.76
(9.41 - 12.11)
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PB-Exposed
Adj. Mean
(95% CI)
11.25
(9.93 - 12.58)
11.00
(9.71 - 12.29)
9.14
(7.88 - 10.41)
10.49
(9.44 - 11.53)
52.30
(49.24 - 55.35)
8.75
(7.37 - 10.13)

F value
(p-value)
2.522
(0.119)
4.743
(0.035)
11.502
(0.001)
1.233
(0.273)
1.744
0.193
4.397
(0.042)

Vocabulary

Information
15

15

Scaled Score

Scaled Score

*
10

5

10

5

0

0
Control

Control

PB

Arithmetic

Digit Span
15

**
*

Scaled Score

Scaled Score

15

10

5

0
Control

10

5

0

PB

Control

PB

IR-Story Memory

Sentence Memory
60

15

Scaled Score

Scaled Score

PB

40

20

0

*

10

5

0
Control

PB

Control

PB

Figure 2 Mean Performance on Verbal Subtests of the Neuropsychological Battery by
Exposure Group. Vertical bars represent the 95% CI. Data were analyzed with univariate
ANCOVA and adjusted for maternal FSIQ, * p < 0.05, ** p < 0.01.
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APPENDIX

APPENDIX A. ADJUSTED MEANS FOR PERFORMANCE ON VERBAL MEASURES
BY SEX AND EXPOSURE GROUP FOLLOWING MULTIVARIATE ANCOVA.
Means are adjusted for maternal FSIQ. Phenobarbital-exposed children performed
significantly worse on verbal measures than control children (p < 0.05). There was no effect
of sex (p > 0.05) or an interaction effect (p > 0.05).
Verbal Subtest
Females
Information

Males
Total
Females

Vocabulary

Males
Total
Females

Arithmetic

Males
Total
Females

Digit Span

Males
Total
Females

Sentence Memory

Males
Total
Females

Immediate Recall Story
Memory

Males
Total

Control
Adj. Mean
(95% CI)
13.22
(11.52 - 14.91)
11.97
(9.90 - 14.05)
12.59
(11.25 - 13.94)
13.29
(11.64 - 14.94)
12.48
(10.46 - 14.50)
12.88
(11.58 - 14.19)
12.41
(10.78 -14.04)
11.74
(9.75 - 13.73)
12.07
(10.79 - 13.36)
11.94
(10.62 - 13.25)
10.33
(8.72 – 11.94)
11.13
(10.09 - 12.17)
57.77
(54.05 - 61.50)
51.13
(46.56 - 55.69)
54.45
(51.50 - 57.40)
10.13
(8.38 - 11.88)
11.72
(9.58 - 13.86)
10.92
(9.54 - 12.31)
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PB-Exposed
Adj. Mean
(95% CI)
11.26
(9.51 - 13.01)
11. 237
(9.16 - 13.3)
11.25
(9.89 - 12.61)
11.40
(9.70 - 13.11)
10.43
(8.40 - 12.46)
10.92
(9.59 - 12.24)
8.81
(7.13 - 10.49)
9.62
(7.62 - 11.61)
9.21
(7.90 - 10.52)
10.38
(9.03 - 11.74)
10.63
(9.02 - 12.24)
10.51
(9.45 - 11.56)
52.85
(49.00 - 56.70)
51.52
(46.94 - 56.10)
52.19
(49.19 - 55.18)
9.03
(7.22 - 10.84)
8.35
(6.20 - 10.50)
8.69
(7.28 - 10.10)

F value
(p-value)
--1.994
(0.165)
--4.493
(0.04)
--9.805
(0.003)
--0.720
(0.401)
--1.170
(0.285)
--5.173
(0.028)
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